Varian Medical Systems and BrainLAB AG yesterday announced they have already booked 14 orders for the new Novalis Tx radiosurgical platform, which combines technologies from both companies to offer noninvasive treatment options for patients.
The orders for the Novalis Tx platform, launched in September 2007, include 10 in the United States and four in Europe.
"Novalis Tx orders have come in at twice the rate normally seen for any type of radiosurgical device and we are delighted with the early response from the surgical community," says Dow Wilson, President of Varian’s Oncology Systems business. "We have received orders from some of the world’s leading surgical and radiotherapy centers as well as from community hospitals that are intent on enhancing their radiosurgical capabilities."
Novalis Tx features a wide range of treatment options for a large number of indications, including malignant and benign lesions, brain metastases, arteriovascular malformations, and functional lesions. According to the companies, the technology features the highest dose delivery rates in the industry, dynamic ultra-fine beam shaping, and frameless patient positioning for faster, more effective, and comfortable treatments.
